Fortunato Ciardiello

Summary

Publications

  1. ncbi request reprint Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor
    F Ciardiello
    Cattedra di Oncologia Medica, Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Universita degli Studi di Napoli Federico II, Naples, Italy
    Clin Cancer Res 6:2053-63. 2000
  2. ncbi request reprint Resistance to taxanes is induced by c-erbB-2 overexpression in human MCF-10A mammary epithelial cells and is blocked by combined treatment with an antisense oligonucleotide targeting type I protein kinase A
    F Ciardiello
    Cattedra di Oncologia Medica, Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Facolta di Medicina e Chirurgia, Universita degli Studi di Napoli Federico II, Naples, Italy
    Int J Cancer 85:710-5. 2000
  3. ncbi request reprint Anti-epidermal growth factor receptor drugs in cancer therapy
    Fortunato Ciardiello
    Cattedra di Oncologia Medica, Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Universita di Napoli Federico II, Via S Pansini 5, 80131 Naples, Italy
    Expert Opin Investig Drugs 11:755-68. 2002
  4. ncbi request reprint Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase
    Fortunato Ciardiello
    Cattedra di Oncologia Medica, Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Universita degli Studi di Napoli Federico II, 5 80131 Naples, Italy
    Clin Cancer Res 9:1546-56. 2003
  5. ncbi request reprint ZD1839 (IRESSA), an EGFR-selective tyrosine kinase inhibitor, enhances taxane activity in bcl-2 overexpressing, multidrug-resistant MCF-7 ADR human breast cancer cells
    Fortunato Ciardiello
    Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Universita di Napoli Federico II, Naples, Italy
    Int J Cancer 98:463-9. 2002
  6. ncbi request reprint A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor
    F Ciardiello
    Cattedra di Oncologia Medica, Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Universita di Napoli Federico II, Via S Pansini 5, 80131 Naples, Italy
    Clin Cancer Res 7:2958-70. 2001
  7. ncbi request reprint Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor
    F Ciardiello
    Cattedra di Oncologia Medica, Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Universita degli Studi di Napoli Federico II, 80131 Naples, Italy
    Clin Cancer Res 7:1459-65. 2001
  8. ncbi request reprint Epidermal growth factor receptor tyrosine kinase inhibitors as anticancer agents
    F Ciardiello
    Cattedra di Oncologia Medica, Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Universita degli Studi di Napoli Federico II, Italy
    Drugs 60:25-32; discussion 41-2. 2000
  9. ncbi request reprint Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells
    F Ciardiello
    Cattedra di Oncologia Medica, Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Facolta di Medicina e Chirurgia, Universita degli Studi di Napoli Federico II, Naples, Italy
    Clin Cancer Res 6:3739-47. 2000
  10. ncbi request reprint Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy
    Fortunato Ciardiello
    Cattedra di Oncologia Medica, Dipartimento Medico Chirurgico di Internistica Clinica e Sperimentale F Magrassi e A Lanzara, Seconda Universita degli Studi di Napoli, Naples, Italy
    Clin Cancer Res 10:784-93. 2004

Detail Information

Publications96

  1. ncbi request reprint Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor
    F Ciardiello
    Cattedra di Oncologia Medica, Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Universita degli Studi di Napoli Federico II, Naples, Italy
    Clin Cancer Res 6:2053-63. 2000
    ..These results demonstrate the antitumor effect of this EGFR-selective tyrosine kinase inhibitor and provide a rationale for its clinical evaluation in combination with cytotoxic drugs...
  2. ncbi request reprint Resistance to taxanes is induced by c-erbB-2 overexpression in human MCF-10A mammary epithelial cells and is blocked by combined treatment with an antisense oligonucleotide targeting type I protein kinase A
    F Ciardiello
    Cattedra di Oncologia Medica, Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Facolta di Medicina e Chirurgia, Universita degli Studi di Napoli Federico II, Naples, Italy
    Int J Cancer 85:710-5. 2000
    ....
  3. ncbi request reprint Anti-epidermal growth factor receptor drugs in cancer therapy
    Fortunato Ciardiello
    Cattedra di Oncologia Medica, Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Universita di Napoli Federico II, Via S Pansini 5, 80131 Naples, Italy
    Expert Opin Investig Drugs 11:755-68. 2002
    ..Results from Phase I - II trials in advanced cancer demonstrate that these drugs have an acceptable tolerability and an interesting clinical activity in patients with a variety of tumour types...
  4. ncbi request reprint Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase
    Fortunato Ciardiello
    Cattedra di Oncologia Medica, Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Universita degli Studi di Napoli Federico II, 5 80131 Naples, Italy
    Clin Cancer Res 9:1546-56. 2003
    ..ZD6474 is a p.o. bioavailable, VEGF flk-1/KDR receptor (VEGFR-2) tyrosine kinase inhibitor with antitumor activity in many human cancer xenografts and is currently in Phase I clinical development...
  5. ncbi request reprint ZD1839 (IRESSA), an EGFR-selective tyrosine kinase inhibitor, enhances taxane activity in bcl-2 overexpressing, multidrug-resistant MCF-7 ADR human breast cancer cells
    Fortunato Ciardiello
    Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Universita di Napoli Federico II, Naples, Italy
    Int J Cancer 98:463-9. 2002
    ..These results demonstrate the ability of ZD1839 to overcome taxane resistance in a model of hormone-independent, multidrug-resistant, human breast cancer...
  6. ncbi request reprint A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor
    F Ciardiello
    Cattedra di Oncologia Medica, Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Universita di Napoli Federico II, Via S Pansini 5, 80131 Naples, Italy
    Clin Cancer Res 7:2958-70. 2001
    ..This mini-review describes the EGFR inhibitors in clinical development...
  7. ncbi request reprint Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor
    F Ciardiello
    Cattedra di Oncologia Medica, Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Universita degli Studi di Napoli Federico II, 80131 Naples, Italy
    Clin Cancer Res 7:1459-65. 2001
    ....
  8. ncbi request reprint Epidermal growth factor receptor tyrosine kinase inhibitors as anticancer agents
    F Ciardiello
    Cattedra di Oncologia Medica, Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Universita degli Studi di Napoli Federico II, Italy
    Drugs 60:25-32; discussion 41-2. 2000
    ..Preclinical data for ZD1839 strongly support the possibility of potentiating the antitumour activity of conventional chemotherapy with agents that selectively block the EGFR...
  9. ncbi request reprint Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells
    F Ciardiello
    Cattedra di Oncologia Medica, Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Facolta di Medicina e Chirurgia, Universita degli Studi di Napoli Federico II, Naples, Italy
    Clin Cancer Res 6:3739-47. 2000
    ..Finally, a significant potentiation in inhibition of VEGF expression and little or no microvessels were observed in GEO tumors after the combined treatment with the two agents...
  10. ncbi request reprint Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy
    Fortunato Ciardiello
    Cattedra di Oncologia Medica, Dipartimento Medico Chirurgico di Internistica Clinica e Sperimentale F Magrassi e A Lanzara, Seconda Universita degli Studi di Napoli, Naples, Italy
    Clin Cancer Res 10:784-93. 2004
    ..ZD6474 is a small molecule VEGF flk-1/KDR (VEGFR-2) tyrosine kinase inhibitor that also demonstrates inhibitory activity against EGFR tyrosine kinase...
  11. ncbi request reprint Combined targeted inhibition of bcl-2, bcl-XL, epidermal growth factor receptor, and protein kinase A type I causes potent antitumor, apoptotic, and antiangiogenic activity
    Giampaolo Tortora
    Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Universita di Napoli Federico II, 80131 Napoli, Italy
    Clin Cancer Res 9:866-71. 2003
    ....
  12. ncbi request reprint Combined targeting of epidermal growth factor receptor and MDM2 by gefitinib and antisense MDM2 cooperatively inhibit hormone-independent prostate cancer
    Roberto Bianco
    Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Universita di Napoli Federico II, Naples, Italy
    Clin Cancer Res 10:4858-64. 2004
    ..For this purpose, we have used the EGFR tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) and a second generation hybrid oligonucleotide antisense MDM2 (AS-MDM2), respectively...
  13. doi request reprint Synergistic antitumor activity of sorafenib in combination with epidermal growth factor receptor inhibitors in colorectal and lung cancer cells
    Erika Martinelli
    Dipartimento Medico Chirurgico di Internistica Clinica e Sperimentale F Magrassi e A Lanzara, Seconda Universita degli Studi di Napoli, Napoli, Italy
    Clin Cancer Res 16:4990-5001. 2010
    ..Cancer cell survival, invasion, and metastasis depend on cancer cell proliferation and on tumor-induced angiogenesis. We evaluated the efficacy of the combination of sorafenib and erlotinib or cetuximab...
  14. ncbi request reprint Novel toll-like receptor 9 agonist induces epidermal growth factor receptor (EGFR) inhibition and synergistic antitumor activity with EGFR inhibitors
    Vincenzo Damiano
    Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Istituto di Anatomia Patologica, and Dipartimento di Biologia e Patologia Cellulare e Molecolare, Universita di Napoli Federico II, Via S Pansini 5, 80131 Naples, Italy
    Clin Cancer Res 12:577-83. 2006
    ..We hypothesized that modified TLR9 agonists could impair epidermal growth factor receptor (EGFR) signaling and, by this means, greatly enhance EGFR inhibitors effect, acting on both the receptor targeting and the immunologic arm...
  15. ncbi request reprint Cooperative antitumor effect of multitargeted kinase inhibitor ZD6474 and ionizing radiation in glioblastoma
    Vincenzo Damiano
    Cattedra di Oncologia Medica, Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Universita di Napoli Federico II, Italy
    Clin Cancer Res 11:5639-44. 2005
    ..We have investigated the antitumor and antiangiogenic effect of ZD6474, an inhibitor of both VEGFR and EGFR signaling as a single agent and in combination with ionizing radiation...
  16. ncbi request reprint Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa)
    Cataldo Bianco
    Cattedra di Oncologia Medica, Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Universita degli Studi di Napoli Federico II, 80131 Naples, Italy
    Clin Cancer Res 8:3250-8. 2002
    ..The antitumor activity of this combination was also tested in nude mice bearing established GEO colon cancer xenografts...
  17. ncbi request reprint Antitumor activity of ZD6474, a vascular endothelial growth factor-2 and epidermal growth factor receptor small molecule tyrosine kinase inhibitor, in combination with SC-236, a cyclooxygenase-2 inhibitor
    Concetta Tuccillo
    Dipartimento Medico Chirurgico di Internistica Clinica e Sperimentale F Magrassi e A Lanzara, Seconda Universita degli Studi di Napoli, Via S Pansini 5, 80131 Naples, Italy
    Clin Cancer Res 11:1268-76. 2005
    ..We investigated the activity of ZD6474 in combination with SC-236, a selective COX-2 inhibitor, to determine the antitumor activity of the simultaneous blockade of EGFR, COX-2, and VEGF functions...
  18. ncbi request reprint Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect
    Giampaolo Tortora
    Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Universita di Napoli Federico II, 80131 Napoli, Italy
    Clin Cancer Res 9:1566-72. 2003
    ..Therefore, we investigated whether any cooperative antitumor effect can be obtained by the combined blockade of COX-2, EGFR, and PKAI...
  19. doi request reprint Vascular endothelial growth factor receptor-1 contributes to resistance to anti-epidermal growth factor receptor drugs in human cancer cells
    Roberto Bianco
    Cattedra di Oncologia Medica, Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Universita di Napoli Federico II, Via S Pansini 5, Naples, Italy
    Clin Cancer Res 14:5069-80. 2008
    ..Combined inhibition of EGFR and other signaling proteins has become a successful therapeutic approach, stimulating the search for further determinants of resistance as basis for novel therapeutic strategies...
  20. ncbi request reprint Zoledronic acid cooperates with a cyclooxygenase-2 inhibitor and gefitinib in inhibiting breast and prostate cancer
    Davide Melisi
    Cattedra di Oncologia Medica, Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Universita di Napoli Federico II, Naples, Italy
    Endocr Relat Cancer 12:1051-8. 2005
    ....
  21. ncbi request reprint Prognostic significance of epidermal growth factor receptor expression in colon cancer patients undergoing curative surgery
    Gennaro Galizia
    Division of Surgical Oncology, F Magrassi and A Lanzara Department of Clinical and Experimental Medicine and Surgery, Second University of Naples School of Medicine, Naples, 80131, Italy
    Ann Surg Oncol 13:823-35. 2006
    ..To investigate the role of epidermal growth factor receptor (EGFR) expression as a prognostic marker for prediction of cancer behavior and clinical outcomes in colon cancer patients undergoing potentially curative surgery...
  22. doi request reprint Weekly chemotherapy with cisplatin and paclitaxel and concurrent radiation therapy as preoperative treatment in locally advanced esophageal cancer: a phase II study
    Michele Orditura
    Division of Medical Oncology, Department of Clinical and Experimental Medicine and Surgery F Magrassi e A Lanzara, Second University of Naples, School of Medicine, Naples, Italy
    Cancer Invest 28:820-7. 2010
    ..The EUS maximal transverse cross sectional area reduction >50% significantly correlated with pathCR. Three-year survival rate was 35%. These results support the activity and mild toxicity of this regimen...
  23. pmc Antitumor activity of sorafenib in human cancer cell lines with acquired resistance to EGFR and VEGFR tyrosine kinase inhibitors
    Floriana Morgillo
    Division of Medical Oncology, Department of Clinical and Experimental Medicine and Surgery F Magrassi e A Lanzara Second University of Naples, Naples, Italy
    PLoS ONE 6:e28841. 2011
    ..These data suggest that resistance to EGFR inhibitors is predominantly driven by the RAS/RAF/MAPK pathway and can be overcame by treatment with sorafenib...
  24. pmc TLR9 agonist acts by different mechanisms synergizing with bevacizumab in sensitive and cetuximab-resistant colon cancer xenografts
    Vincenzo Damiano
    Departments of Endocrinologia e Oncologia Molecolare e Clinica, Universita di Napoli Federico II, 80131 Napoli, Italy
    Proc Natl Acad Sci U S A 104:12468-73. 2007
    ....
  25. doi request reprint Antitumor activity of bortezomib in human cancer cells with acquired resistance to anti-epidermal growth factor receptor tyrosine kinase inhibitors
    Floriana Morgillo
    Oncologia Medica, Dipartimento Medico Chirurgico di Internistica Clinica e Sperimentale F Magrassi e A Lanzara, Seconda Universita degli Studi di Napoli, Via S Pansini 5, 80131 Naples, Italy
    Lung Cancer 71:283-90. 2011
    ..These results suggest that bortezomib treatment could be a useful approach to overcome resistance to anti-EGFR therapies...
  26. doi request reprint Sequence-dependent, synergistic antiproliferative and proapoptotic effects of the combination of cytotoxic drugs and enzastaurin, a protein kinase Cbeta inhibitor, in non-small cell lung cancer cells
    Floriana Morgillo
    Dipartimento Medico Chirurgico di Internistica Clinica e Sperimentale, F Magrassi e A Lanzara, Seconda Universita degli Studi di Napoli, Via S Pansini 5, 80131 Naples, Italy
    Mol Cancer Ther 7:1698-707. 2008
    ..In contrast, the concomitant treatments or the sequential treatments, in which enzastaurin was given before chemotherapy, resulted in significant antagonistic effects...
  27. ncbi request reprint Antiangiogenic drugs in non-small cell lung cancer treatment
    Tina Cascone
    Cattedra di Oncologia Medica, Dipartimento Medico Chirurgico di Internistica Clinica e Sperimentale F Magrassi e A Lanzara, Seconda Universita degli Studi di Napoli, Naples, Italy
    Curr Opin Oncol 18:151-5. 2006
    ..This review focuses on the available clinical data on drugs targeting the vascular endothelial growth factor - vascular endothelial growth factor receptor pathway in the treatment of non-small cell lung cancer...
  28. doi request reprint Synergistic anti-proliferative and pro-apoptotic activity of combined therapy with bortezomib, a proteasome inhibitor, with anti-epidermal growth factor receptor (EGFR) drugs in human cancer cells
    Tina Cascone
    Division of Medical Oncology, Department of Clinical and Experimental Medicine and Surgery F Magrassi and A Lanzara, Second University of Naples, Naples, Italy
    J Cell Physiol 216:698-707. 2008
    ....
  29. ncbi request reprint ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases
    Francesca Carlomagno
    Istituto di Endocrinologia ed Oncologia Sperimentale del Consiglio Nazionale delle Ricerche, Dipartimento di Biologia e Patologia Cellulare e Molecolare Luigi Califano, University Federico II, Naples, Italy
    Cancer Res 62:7284-90. 2002
    ..Thus, targeting RET oncogenes with ZD6474 might offer a potential treatment strategy for carcinomas sustaining oncogenic activation of RET...
  30. doi request reprint Adjuvant chemoradiotherapy in patients with stage III or IV radically resected gastric cancer: a pilot study
    Michele Orditura
    Division of Medical Oncology, F Magrassi A Lanzara Department of Clinical and Experimental Medicine and Surgery, Second University of Naples School of Medicine, c o II Policlinico, Via Pansini 5, Naples, Italy
    Arch Surg 145:233-8. 2010
    ..We assessed the feasibility and toxic effects of chemoradiotherapy as adjuvant treatment in locally advanced gastric cancer...
  31. ncbi request reprint Determination of molecular marker expression can predict clinical outcome in colon carcinomas
    Gennaro Galizia
    Division of Surgical Oncology, Second University of Naples School of Medicine, Naples, Italy
    Clin Cancer Res 10:3490-9. 2004
    ..involved in cell cycle regulation (p27 and p53), apoptosis (p53 and p27), and tumor neoangiogenesis [p53, vascular endothelial growth factor (VEGF), and microvessel count] in predicting tumor behavior and clinical outcome in CRC patients..
  32. ncbi request reprint Combined targeted therapies in non-small cell lung cancer: a winner strategy?
    Tina Cascone
    Dipartimento Medico Chirurgico di Internistica Clinica e Sperimentale F Magrassi e A Lanzara, Seconda Universita degli Studi di Napoli, Naples, Italy
    Curr Opin Oncol 19:98-102. 2007
    ..The complexity of the signalling process leading to cancer cell proliferation and to the neoplastic phenotype supports the necessity of interfering at different stages to avoid cancer cell resistance to therapy...
  33. doi request reprint Implications of KRAS mutation status for the treatment of metastatic colorectal cancer
    Fortunato Ciardiello
    Division of Medical Oncology, Department of Experimental and Clinical Medicine and Surgery F Magrassi and A Lanzara, Second University of Naples, Naples, Italy
    Target Oncol 4:311-22. 2009
    ..In view of this, testing for tumor KRAS mutation status should be mandatory at diagnosis of mCRC, prior to treatment decision-making...
  34. doi request reprint Quality of life analysis of TORCH, a randomized trial testing first-line erlotinib followed by second-line cisplatin/gemcitabine chemotherapy in advanced non-small-cell lung cancer
    Massimo Di Maio
    Clinical Trials Unit, National Cancer Institute, Naples, Italy
    J Thorac Oncol 7:1830-44. 2012
    ..The trial, designed to test noninferiority in overall survival, was stopped at interim analysis because of inferior survival in the experimental arm. Quality of life (QoL), a secondary outcome, is reported here...
  35. ncbi request reprint Combination of standard chemotherapy and targeted agents
    Maria Anna Bareschino
    Dipartimento Medico Chirurgico di Internistica Clinica e Sperimentale F Magrassi e A Lanzara, Seconda Universita degli Studi di Napoli, Naples, Italy
    J Thorac Oncol 2:S19-23. 2007
  36. doi request reprint Perspectives in adjuvant therapy of gastric cancer
    Ferdinando De Vita
    Medical Oncology, Department of Clinical and Experimental Medicine F Magrassi and A Lanzara, Second University of Naples, Naples, Italy
    Oncology 77:38-42. 2009
    ..Therefore, at present the routine use of adjuvant therapy should be regarded as an investigational approach. Improved clinical trial designs with standardized surgical techniques and the incorporation of newer active drugs are needed...
  37. pmc Hepatoid carcinoma colliding with a liposarcoma of the left colon serosa presenting as an abdominal mass
    Michele Orditura
    Cattedra di Oncologia Medica, Seconda Università degli Studi di Napoli Ospedale Da Procida, Salerno, Naples, Italy
    World J Surg Oncol 5:42. 2007
    ..Stomach is the most frequent site where hepatoid adenocarcinoma occurs, although it has been described in many other organs. On the other side, liposarcoma is a rare, malignant tumor that develops from fat cells...
  38. ncbi request reprint The use of xenograft models for the selection of cancer treatments with the EGFR as an example
    Teresa Troiani
    Dipartimento Medico Chirurgico di Internistica Clinica e Sperimentale F Magrassi e A Lanzara, Seconda Universita degli Studi di Napoli, Naples, Italy
    Crit Rev Oncol Hematol 65:200-11. 2008
    ..Here we review the value and the limitations of xenograft models and their role in developing new anti-cancer treatments...
  39. doi request reprint Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications
    Giampaolo Tortora
    Clinical Unit and Laboratories of Molecular Therapy at the University of Naples Federico II, Naples, Italy
    Nat Clin Pract Oncol 5:521-30. 2008
    ..This Review discusses the experimental rationale for, preclinical studies of and clinical trials on combined blockade of ERBB and VEGF signaling...
  40. ncbi request reprint Correlation between efficacy and skin rash occurrence following treatment with the epidermal growth factor receptor inhibitor cetuximab: a single institution retrospective analysis
    Michele Orditura
    Division of Medical Oncology, F Magrassi A Lanzara Department of Clinical and Experimental Medicine, Second University of Naples School of Medicine, c o II Policlinico, 80131 Naples, Italy
    Oncol Rep 21:1023-8. 2009
    ..Skin toxicity was confirmed as the only clinical variable able to predict the response to cetuximab...
  41. doi request reprint Emerging VEGF-receptor inhibitors for colorectal cancer
    Erika Martinelli
    Oncologia Medica and Immunologia Clinica, Dipartimento Medico Chirurgico di Internistica Clinica e Sperimentale F Magrassi e A Lanzara, Seconda Universita degli Studi di Napoli, Via S Pansini 5, 80131 Napoli, Italia
    Expert Opin Emerg Drugs 18:25-37. 2013
    ..Bevacizumab, the first anti-angiogenetic agent approved for the treatment of mCRC provide a proof of concept since it has improved the progression-free survival and overall survival when combined with cytotoxic chemotherapy...
  42. doi request reprint Implications for KRAS status and EGFR-targeted therapies in metastatic CRC
    Nicola Normanno
    Cell Biology and Biotherapy Unit, INT Fondazione Pascale, Naples, Italy
    Nat Rev Clin Oncol 6:519-27. 2009
    ..We summarize the experimental and clinical evidence supporting the use of KRAS testing for the optimal selection of patients with mCRC to be treated with anti-EGFR monoclonal antibodies...
  43. ncbi request reprint External beam radiotherapy in bone metastatic prostate cancer: impact on patients' pain relief and quality of life
    Giuseppe Di Lorenzo
    Cattedra di Oncologia Medica, Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Universita degli Studi di Napoli Federico II, Napoli, Italy
    Oncol Rep 10:399-404. 2003
    ..Minimal side effects were experienced and QoL improved as shown by the results of the specific questionnaire...
  44. ncbi request reprint Pegylated liposomal doxorubicin: pharmacologic and clinical evidence of potent antitumor activity with reduced anthracycline-induced cardiotoxicity (review)
    Michele Orditura
    Division of Medical Oncology, F Magrassi A Lanzara Department of Clinical and Experimental Medicine and Surgery, Second University of Naples School of Medicine, Via S Pansini 5, 80131 Naples, Italy
    Oncol Rep 12:549-56. 2004
    ..Here, we review the pharmacologic properties of PLD as well as the results of phases I, II and III trials demonstrating activity and low cardiac toxicity associated with the use of this novel drug...
  45. pmc Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies
    Giampaolo Tortora
    Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Universita di Napoli Federico II, Naples, Italy
    Drug Resist Updat 10:81-100. 2007
    ....
  46. ncbi request reprint Rational bases for the development of EGFR inhibitors for cancer treatment
    Roberto Bianco
    Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Universita di Napoli Federico II, Via S Pansini 5, 80131 Naples, Italy
    Int J Biochem Cell Biol 39:1416-31. 2007
    ..This article reviews the EGFR role in carcinogenesis and tumor progression as rational bases for the development of specific therapeutic inhibitors...
  47. ncbi request reprint Primary and acquired resistance to anti-EGFR targeted drugs in cancer therapy
    Floriana Morgillo
    Dipartimento Medico Chirurgico di Internistica Clinica e Sperimentale F Magrassi e A Lanzara, Seconda Universita degli Studi di Napoli, Via Pansini 5 80131 Napoli, Italy
    Differentiation 75:788-99. 2007
    ..This review will focus on the most relevant mechanisms contributing to the acquisition of sensitivity/resistance to EGFR inhibitors...
  48. ncbi request reprint The role of EGFR inhibitors in nonsmall cell lung cancer
    Fortunato Ciardiello
    Cattedra di Oncologia Medica, Dipartimento Medico Chirurgico di Internistica Clinica e Sperimentale F Magrassi e A Lanzara, Seconda Universita degli Studi di Napoli, Naples, Italy
    Curr Opin Oncol 16:130-5. 2004
    ..Several antiepidermal growth factor receptor agents are in clinical development. This review focuses on the available clinical data on epidermal growth factor receptor-targeting drugs in the treatment of nonsmall cell lung cancer...
  49. ncbi request reprint Epidermal growth factor receptor tyrosine kinase inhibitors in late stage clinical trials
    Fortunato Ciardiello
    Cattedra di Oncologia Medica, Dipartimento Medico Chirurgico di Internistica Clinica e Sperimentale F Magrassi e A Lanzara, Seconda Universita degli Studi di Napoli, Via S Pansini 5, 80131 Napoli, Italy
    Expert Opin Emerg Drugs 8:501-14. 2003
    ..Furthermore, continuing clinical trials and a series of open clinical issues for the development of optimal strategies of using EGFR-targeting agents will be discussed...
  50. doi request reprint Beyond bevacizumab: new anti-VEGF strategies in colorectal cancer
    Teresa Troiani
    Oncologia Medica, Dipartimento Medico Chirurgico di Internistica Clinica e Sperimentale F Magrassi e A Lanzara, Seconda Universita degli Studi di Napoli, Via S Pansini 5, 80131 Napoli, Italia
    Expert Opin Investig Drugs 21:949-59. 2012
    ....
  51. ncbi request reprint p27 downregulation and metallothionein overexpression in gastric cancer patients are associated with a poor survival rate
    Gennaro Galizia
    Division of Surgical Oncology, F Magrassi A Lanzara Department of Clinical and Experimental Medicine and Surgery, Second University of Naples School of Medicine, Naples, Italy
    J Surg Oncol 93:241-52. 2006
    ....
  52. ncbi request reprint Intrinsic and acquired resistance to EGFR inhibitors in human cancer therapy
    Roberto Bianco
    Dipartimento di Endocrinologia Molecolare e Clinica, Universita degli Studi di Napoli Federico II, Naples, Italy
    Endocr Relat Cancer 12:S159-71. 2005
    ..However, the intrinsic molecular mechanisms of resistance to these drugs are still unclear. This review will focus on the preclinical findings on therapeutic resistance to EGFR targeting agents...
  53. ncbi request reprint Key cancer cell signal transduction pathways as therapeutic targets
    Roberto Bianco
    Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Universita di Napoli Federico II, Via S Pansini 5, 80131 Napoli, Italy
    Eur J Cancer 42:290-4. 2006
    ....
  54. ncbi request reprint Chemosensitization by antisense oligonucleotides targeting MDM2
    Roberto Bianco
    Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Universita di Napoli Federico II, Via S Pansini 5, 80131 Naples, Italy
    Curr Cancer Drug Targets 5:51-6. 2005
    ....
  55. ncbi request reprint In vitro expansion of human breast cancer epithelial and mesenchymal stromal cells: optimization of a coculture model for personalized therapy approaches
    Bianca Maria Veneziani
    Dipartimento di Biologia e Patologia Cellulare e Molecolare L Califano, Universita di Napoli Federico II, Via S Pansini 5, 80131 Naples, Italy
    Mol Cancer Ther 6:3091-100. 2007
    ....
  56. doi request reprint Synergistic effects of metformin treatment in combination with gefitinib, a selective EGFR tyrosine kinase inhibitor, in LKB1 wild-type NSCLC cell lines
    Floriana Morgillo
    Oncologia Medica, Dipartimento Medico Chirurgico di Internistica Clinica e Sperimentale F Magrassi e A Lanzara, Seconda Universita degli Studi di Napoli, Naples, Italy
    Clin Cancer Res 19:3508-19. 2013
    ..Metformin is a widely used antidiabetic drug and also displays significant growth-inhibitory and proapoptotic effects in several cancer models, alone or in combination with chemotherapeutic drugs...
  57. ncbi request reprint Angiogenesis: a target for cancer therapy
    Giampaolo Tortora
    Division of Medical Oncology, Department of Molecular and Clinical Endocrinology and Oncology, Universita di Napoli Federico II, Via S Pansini 5, 80131 Naples, Italy
    Curr Pharm Des 10:11-26. 2004
    ..In this review will be discussed the signal transduction mechanisms of angiogenic molecules, the development of specific inhibitors and their translation into clinical studies and, finally, the new perspectives in antiangiogenic therapy...
  58. doi request reprint EGFR antagonists in cancer treatment
    Fortunato Ciardiello
    Division of Medical Oncology, Department of Experimental and Clinical Medicine and Surgery F Magrassi and A Lanzara, Second University of Naples, Naples, Italy
    N Engl J Med 358:1160-74. 2008
  59. doi request reprint EGFR-targeted therapy
    Loredana Vecchione
    Digestive Oncology Unit, University Hospital Gasthuisberg, Herestraat 49 bus 602 Be 3000, Leuven, Belgium
    Exp Cell Res 317:2765-71. 2011
    ....
  60. ncbi request reprint Cetuximab in the treatment of colorectal cancer
    Fortunato Ciardiello
    Seconda Universita degli Studi di Napoli, Cattedra di Oncologia Medica, Dipartimento Medico Chirurgico di Internistica Clinica Sperimentale F Magrassi e A Lanzara, Via S Pansini 5, 80131 Napoli, Italy
    Future Oncol 1:173-81. 2005
    ....
  61. ncbi request reprint Antisense strategies targeting protein kinase C: preclinical and clinical development
    Giampaolo Tortora
    Department of Molecular and Clinical Endocrinology and Oncology, Universita di Napoli Federico II, Naples, Italy
    Semin Oncol 30:26-31. 2003
    ..Studies in other tumor types will also investigate the benefit of combining LY900003 with conventional chemotherapy...
  62. ncbi request reprint Protein kinase A as target for novel integrated strategies of cancer therapy
    Giampaolo Tortora
    Cattedra di Oncologia Medica, Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Universita di Napoli Federico II, 80131 Napoli, Italy
    Ann N Y Acad Sci 968:139-47. 2002
    ..Finally, we have shown that AS-PKA-I also has antitumor and antiangiogenic effects following oral administration and that they can be greatly enhanced in combination with oral ZD1839 and oral taxanes...
  63. doi request reprint Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells
    Erika Martinelli
    Oncologia Medica, Dipartimento Medico Chirurgico di Internistica Clinica e Sperimentale F Magrassi e A Lanzara, Seconda Universita degli Studi di Napoli, Via S Pansini 5, 80131, Napoli, Italia
    Int J Cancer 133:2089-101. 2013
    ..These results suggest that dual blockade of MAPK and PI3K pathways could overcome intrinsic resistance to MEK inhibition. ..
  64. ncbi request reprint [EGF receptor blockade with monoclonal antibodis and so-called "small molecules"]
    Fortunato Ciardiello
    Division of Medical Oncology, Department of Clinical and Experimental Medicine, Seconda Universita di Napoli, Naples, Italy
    Onkologie 28:18-24. 2005
  65. ncbi request reprint Antisense targeting protein kinase A type I as a drug for integrated strategies of cancer therapy
    Giampaolo Tortora
    Division of Medical Oncology, Department of Molecular and Clinical Endocrinology and Oncology, Universita di Napoli Federico II, 80131 Napoli, Italy
    Ann N Y Acad Sci 1002:236-43. 2003
    ..These studies support the development of AS-PKAI as a novel anticancer agent and suggest its potentially relevant role when integrated with conventional treatments and/or other signaling inhibitors in novel therapeutic strategies...
  66. ncbi request reprint Elevated perioperative serum vascular endothelial growth factor levels in patients with colon carcinoma
    Ferdinando De Vita
    Division of Medical Oncology, F Magrassi A Lanzara Department of Clinical and Experimental Medicine, Second University of Naples School of Medicine, II Policlinico, Via S Pansini 5, 90131 Naples, Italy
    Cancer 100:270-8. 2004
    ....
  67. pmc Detection of erbB2 copy number variations in plasma of patients with esophageal carcinoma
    Immacolata Andolfo
    CEINGE, Centro di Ingegneria Genetica e Biotecnologia Avanzate, Naples, Italy
    BMC Cancer 11:126. 2011
    ..Here, we sought to isolate cell-free DNA released into the plasma of patients with esophageal carcinoma, to analyze copy number variations of marker genes in the search for early detection of tumor progression...
  68. ncbi request reprint Involvement of growth factor receptors of the epidermal growth factor receptor family in prostate cancer development and progression to androgen independence
    Giuseppe Di Lorenzo
    Department of Molecular and Clinical Endocrinology, Universita degli Studi di Napoli Federico II, Naples, Italy
    Clin Prostate Cancer 2:50-7. 2003
    ....
  69. ncbi request reprint CRIPTO-1: a novel target for therapeutic intervention in human carcinoma
    Nicola Normanno
    Department of Experimental Oncology, INT Fondazione Pascale, Via Mariano Semmola, I 80131 Naples, Italy
    Int J Oncol 25:1013-20. 2004
    ..Taken together, these data strongly suggest that CR-1 might represent a novel target for therapeutic intervention in different carcinoma types...
  70. ncbi request reprint Trying to compose the puzzle with all the pieces: epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer
    Massimo Di Maio
    Clinical Trials Unit, National Cancer Institute of Naples, Naples, Italy
    J Cell Physiol 205:355-63. 2005
    ....
  71. ncbi request reprint Epidermal growth factor receptor inhibitors in cancer treatment
    Fortunato Ciardiello
    Cattedra di Oncologia Medica, Dipartimento Medico Chirurgico di Internistica Clinica e Sperimentale F Magrassi e A Lanzara, Seconda Universita degli Studi di Napoli, Via S Pansini 5, 80131 Napoli, Italy
    Future Oncol 1:221-34. 2005
    ..Furthermore, a series of open clinical issues for the development of optimal strategies of using EGFR-targeting agents will be discussed...
  72. ncbi request reprint The rational basis of using novel targeted biological agents in non-small cell lung cancer
    Fortunato Ciardiello
    Cattedra di Oncologia Medica, Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Universita di Napoli Federico II, Naples, Italy
    Suppl Tumori 1:S31-3. 2002
  73. ncbi request reprint Chronic inflammation and oxidative stress in human carcinogenesis
    Alessandro Federico
    Division of Gastroenterology, F Magrassi and A Lanzara Medical Surgical Department, Second University of Naples, Naples, Italy
    Int J Cancer 121:2381-6. 2007
    ..This review focalizes some of these intricate events by discussing the relationships occurring among oxidative/nitrosative/metabolic stress, inflammation and cancer...
  74. ncbi request reprint Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer
    Giuseppe Di Lorenzo
    Cattedra di Oncologia Medica, Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Universita degli Studi di Napoli Federico II, 80131 Naples, Italy
    Clin Cancer Res 8:3438-44. 2002
    ..We investigated EGFR and c-erbB-2 expression in primary androgen-dependent and in advanced androgen-independent prostate cancer and their potential role as markers of disease progression...
  75. doi request reprint Novel investigational drugs for gastric cancer
    Loredana Vecchione
    Second University of Naples, School of Medicine, Division of Medical Oncology F Magrassi and A Lanzara, Department of Clinical and Experimental Medicine and Surgery, c o II Policlinico Via S Pansini 5, 80131 Naples, Italy
    Expert Opin Investig Drugs 18:945-55. 2009
    ..Several cytotoxic agents have demonstrated activity and combination regimens improve progression-free survival, overall survival and quality of life. Nevertheless, now there is no standard therapy for advanced gastric cancer patients...
  76. ncbi request reprint Understanding the mechanisms of action of EGFR inhibitors in NSCLC: what we know and what we do not know
    David Raben
    University of Colorado Cancer Center, Department of Radiation Oncology, University of Colorado Health Sciences Center, Denver, CO 80010 5010, USA
    Lung Cancer 41:S15-22. 2003
    ....
  77. ncbi request reprint Combining targeted therapies and drugs with multiple targets in the treatment of NSCLC
    Paolo Maione
    Division of Medical Oncology, S G Moscati Hospital, Contrada Amoretta, 83100 Avellino, Italy
    Oncologist 11:274-84. 2006
    ..Whether the multitargeted approach is best performed using combinations of selective agents or agents that intrinsically target various targets is a matter of debate...
  78. ncbi request reprint ZD1839 (Iressa): preclinical studies and pharmacology
    Fortunato Ciardiello
    Dipartimento di Endcorinologia e Oncologia Molecolare e Clinica, Facolta di Medicina e Chirurgia, Universita Federico II, Naples
    Tumori 88:S155-7. 2002
  79. ncbi request reprint Interference with EGFR signaling: paradigm for improving radiation response in cancer treatment
    David Raben
    University of Colorado Health Sciences Center, Anschutz Cancer Pavilion, Department of Radiation Oncology, Aurora 80010 0510, USA
    Expert Rev Anticancer Ther 2:461-71. 2002
    ..Thus, emerging rapidly are cancer treatment strategies based on an improved understanding of the specific cellular and molecular abnormalities of individual tumors...
  80. ncbi request reprint Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft
    David Raben
    Department of Radiation Oncology, University of Colorado Health Sciences Center, Anschutz Cancer Pavilion, 1665 North Ursula Street, Suite 1032, Box F706, Aurora, CO 80010 0510, USA
    Mol Cancer Ther 3:977-83. 2004
    ....
  81. ncbi request reprint Anti-tumor activity of the combination of cetuximab, an anti-EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinases
    Maria Pia Morelli
    Dipartimento Medico Chirurgico di Internistica Clinica e Sperimentale F Magrassi e A Lanzara, Seconda Universita degli Studi di Napoli, Napoli, Italy
    J Cell Physiol 208:344-53. 2006
    ....
  82. ncbi request reprint Sequence-dependent inhibition of human colon cancer cell growth and of prosurvival pathways by oxaliplatin in combination with ZD6474 (Zactima), an inhibitor of VEGFR and EGFR tyrosine kinases
    Teresa Troiani
    University of Colorado Cancer Center, 12801 East 17th Avenue, Aurora, CO 80010, USA
    Mol Cancer Ther 5:1883-94. 2006
    ..ZD6474 in combination with oxaliplatin has synergistic antiproliferative properties in human colorectal cancer cell lines in vitro when oxaliplatin is administered before ZD6474...
  83. ncbi request reprint Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine and ionizing radiation against pancreatic cancer
    Cataldo Bianco
    Division of Radiotherapy, Department of Oncology, Transplants and Advanced Technologies in Medicine, University of Pisa, Pisa, Italy
    Clin Cancer Res 12:7099-107. 2006
    ....
  84. ncbi request reprint ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinase activity in combination with radiotherapy
    Barbara Frederick
    Department of Radiation Oncology, University of Colorado Health Sciences Center, Aurora, CO 80010 0510, USA
    Int J Radiat Oncol Biol Phys 64:33-7. 2006
    ..We also discuss ZD6474 in the context of anti-EGFR therapy resistance. Dual inhibition of EGFR and VEGF receptor signaling pathways shows promise in enhancing RT efficacy...
  85. ncbi request reprint Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib
    Floriana Morgillo
    Department of Thoracic Head and Neck Medical Oncology, M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Cancer Res 13:2795-803. 2007
    ..In this study, we determined whether the insulin-like growth factor I (IGF-I) signaling pathway induces resistance of non-small cell lung cancer (NSCLC) cells to the EGFR tyrosine kinase inhibitor gefitinib...
  86. ncbi request reprint Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/phospho-Akt-positive or never smoker patients with advanced non-small-cell lung cancer: the ONCOBELL trial
    Federico Cappuzzo
    Department of Hematology Oncology, Istituto Clinico Humanitas IRCCS, Rozzano, Italy
    J Clin Oncol 25:2248-55. 2007
    ..The ONCOBELL trial is a prospective phase II study evaluating gefitinib sensitivity in NSCLC patients who never smoked or have increased EGFR gene copy number or activation of the antiapoptotic protein Akt...
  87. ncbi request reprint A randomized phase II study of sorafenib/gemcitabine or sorafenib/erlotinib for advanced non-small-cell lung cancer in elderly patients or patients with a performance status of 2: treatment rationale and protocol dynamics
    Cesare Gridelli
    Division of Medical Oncology, S G Moscati Hospital, Avellino, Italy
    Clin Lung Cancer 8:396-8. 2007
    ..The study will enroll 100 patients: 58 patients aged >or= 70 years with a PS of 0-2 and 42 patients aged < 70 years with a PS of 2. The analysis will be conducted differently for the 2 groups of patients...
  88. ncbi request reprint Epidermal growth factor receptor (EGFR) inhibitors in cancer therapy
    Fortunato Ciardiello
    Division of Medical Oncology, Department of Experimental and Clinical Medicine and Surgery, F Magrassi and A Lanzara, Second University of Naples, Via S Pansini 5, 80131 Napoli, Italy
    Prog Drug Res 63:93-114. 2005
  89. ncbi request reprint Erlotinib in non-small cell lung cancer treatment: current status and future development
    Cesare Gridelli
    Division of Medical Oncology, SG Moscati Hospital, Città Ospedaliera, Contrada Amoretta, Avellino, Italy
    Oncologist 12:840-9. 2007
    ....
  90. ncbi request reprint Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer
    Josep Tabernero
    Medical Oncology Department, Vall d Hebron University Hospital, P Vall d Hebron, 119 129, 08035 Barcelona, Spain
    J Clin Oncol 25:5225-32. 2007
    ....
  91. ncbi request reprint Rational combination of targeted therapies as a strategy to overcome the mechanisms of resistance to inhibitors of EGFR signaling
    Roberto Bianco
    Dipartimento Medico Chirurgico di Internistica Clinica e Sperimentale, Seconda Universita di Napoli, Napoli, Italy
    Curr Pharm Des 13:3358-67. 2007
    ..This review focuses on the role of complementary signalling pathways in the development of resistance to EGFR targeting agents and the rationale to combine novel inhibitors as anticancer therapy...
  92. ncbi request reprint Investigation of two dosing schedules of vandetanib (ZD6474), an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, in combination with irinotecan in a human colon cancer xenograft model
    Teresa Troiani
    Division of Medical Oncology, University of Colorado at Denver and Health Sciences Center, Aurora, Colorado, USA
    Clin Cancer Res 13:6450-8. 2007
    ....
  93. ncbi request reprint The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer
    David Raben
    Tobacco Related Malignancy Program, Department of Radiation Oncology, Anschutz Cancer Pavilion, University of Colorado Health Sciences Center, 1165 North Ursula Street F706, Aurora, CO 80010 0510, USA
    Clin Cancer Res 11:795-805. 2005
    ..In this report, we investigated the cellular and molecular effects of cetuximab alone and in combination with radiation and/or chemotherapy in human NSCLC cell lines with varying levels of EGFR overexpression in vitro and in vivo...
  94. ncbi request reprint Role of the cripto (EGF-CFC) family in embryogenesis and cancer
    Caterina Bianco
    Tumor Growth Factor Section, Mammary Biology and Tumorigenesis Laboratory, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Growth Factors 22:133-9. 2004
  95. ncbi request reprint Potential role of molecularly targeted therapy in the management of advanced nonsmall cell lung carcinoma in the elderly
    Cesare Gridelli
    Division of Medical Oncology, San Giuseppe Moscati Hospital, Avellino, Italy
    Cancer 101:1733-44. 2004
    ..For such elderly patients, alternatives to conventional chemotherapy, such as novel molecularly targeted therapy regimens, are of interest...
  96. doi request reprint Second-line treatment of advanced non-small cell lung cancer
    Cesare Gridelli
    Medical Oncology, S G Moscati Hospital, Avellino, Italy
    J Thorac Oncol 3:430-40. 2008
    ..Further research is mandatory, to find better treatments, and to identify clinical and molecular predictive markers of efficacy, both for chemotherapy and for novel biologic agents...